2 results
Approved WMOCompleted
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
Approved WMOPending
To assess the safety and feasibility of percutaneous CT-or ultrasound-guided RNT using the Oncosil* device in patients with non-progressive LAPC after induction chemotherapy treatment.